OLBA HEALTHCARE HOLDINGS (2689) FY2026 Q2 Earnings Report

Quick View

Executive Summary

The defining characteristic is an increase in revenue accompanied by a decrease in profit, indicating that revenue growth has not translated into earnings growth. Revenue increased to ¥624.4B (+3.0% YoY), while Operating Income declined to ¥6.7B (-16.6%), Ordinary Income to ¥6.8B (-18.0%), and Net Income to ¥4.5B (¥6.5B in the same period of the previous year). Amid a low-margin structure with an 11.1% gross margin, selling, general and administrative expenses increased, causing the Operating Income margin to narrow to 1.1%.

Factors Driving Earnings Fluctuations

【Revenue】Revenue increased 3.0% YoY to ¥624.4B. By segment, MedicalEquipment generated ¥589.2B, accounting for 94.4% of total revenue and representing the core business, followed by SPD at ¥30.3B and CareNursingGoods at ¥14.6B. Expansion in demand for medical equipment distribution is considered the primary driver of revenue growth.

【Profit and Loss】Cost of sales was high at ¥555.0B, representing a cost ratio of 88.9%, leaving gross profit at ¥69.4B, with a gross margin of 11.1%. SG&A expenses increased from the previous year to ¥62.7B, representing an SG&A ratio of 10.0%, and Operating Income contracted to ¥6.7B (-16.6%). Ordinary Income was ¥6.8B (-18.0%), while Net Income was ¥4.5B (¥6.5B in the previous year, -30.5%). Although extraordinary income of ¥0.3B slightly increased Profit Before Tax, the decline in Net Income was greater than that in Operating Income due in part to the corporate tax burden. The company is characterized by revenue growth accompanied by earnings decline, with the low gross margin and increased SG&A expenses putting pressure on profitability.

Segment Analysis

MedicalEquipment generated revenue of ¥589.2B and Operating Income of ¥5.6B, representing an Operating Income margin of 0.9% and accounting for 94.4% of total company revenue. It is the core segment, but its profitability is low. SPD generated revenue of ¥30.3B and Operating Income of ¥0.6B, with an Operating Income margin of 2.1%, while CareNursingGoods generated revenue of ¥14.6B and Operating Income of ¥1.2B, with an Operating Income margin of 8.4%. Although these segments are small in scale, their margins are relatively high. The company-wide Operating Income margin of 1.1% is primarily attributable to the low profitability of MedicalEquipment, with the high profitability of the smaller segments providing partial support.

Key Financial Indicators

【Profitability】The Operating Income margin of 1.1% and Net Income margin of 0.7% are both low. While revenue increased 3.0%, Operating Income declined 16.6%, indicating that cost increases are putting pressure on profitability.【Cash Flow Quality】Operating Cash Flow (OCF) was -¥7.7B. The fact that OCF was negative despite Net Income of ¥4.5B indicates challenges in converting earnings into cash. Increases in trade receivables (-¥13.1B) and inventories (-¥9.8B) are putting pressure on working capital.【Investment Efficiency】ROE was 3.7%, primarily due to the low Net Income margin. The ratio of accounts receivable to total assets was high at approximately 49.8%, making accounts receivable management an issue from an asset-efficiency perspective.【Financial Soundness】The Equity Ratio was 25.3%, down from the equivalent of 27.6% in the previous year, while net assets remained nearly flat at ¥121.5B amid an expansion in total assets. Current assets were ¥386.1B against current liabilities of ¥323.0B, leaving the current ratio at approximately 119.5%.

Cash Flow Analysis

Operating Cash Flow (OCF) was -¥7.7B, representing a slight improvement from -¥8.0B in the previous year but remaining negative. Investing Cash Flow was -¥9.8B, with capital expenditures of ¥10.5B reaching approximately three times depreciation and amortization expense of ¥3.5B, placing pressure on cash flow through investment spending. As a result, Free Cash Flow was -¥17.5B, reflecting an outflow of funds from the combination of operating and investing activities. Financing Cash Flow was positive at ¥11.8B, offsetting the cash outflow through an increase in short-term borrowings. Despite securing Operating Income, the company’s negative OCF reflects deterioration in working capital due to increases in trade receivables (-¥13.1B) and inventories (-¥9.8B), indicating challenges in converting earnings into cash.

Earnings Quality

Profit Before Tax was ¥6.9B compared with Ordinary Income of ¥6.8B. Extraordinary income of ¥0.3B, including gains on the sale of investment securities, was the primary reason for the difference. As its scale was limited, the focus of earnings analysis should remain on the trend in Operating Income. Non-operating income and expenses were nearly balanced, with income and expenses both at ¥0.4B; foreign exchange gains of ¥0.2B were the primary source of non-operating income. Comprehensive Income was ¥3.9B, slightly below Net Income of ¥4.5B, reflecting a divergence caused by other comprehensive income items such as foreign currency translation adjustments and valuation differences on securities, which had a negative impact. However, the difference between the two was not significant. Overall, the impact of temporary factors was limited, and the decline in profitability is attributable to structural factors arising from the cost structure of the core business.

Earnings Forecasts and Guidance

Progress against the full-year forecast was 48.8% for Revenue, 33.7% for Operating Income, 35.0% for Ordinary Income, and 34.1% for Net Income. Revenue progress was close to the 50% benchmark as of Q2, but profit progress was 15–16 points below that level in each case, implying that approximately ¥13.3B in Operating Income—the remaining amount against the full-year forecast of ¥20.0B—must be generated in the second half. The full-year forecast calls for revenue and profit growth, with Revenue of +4.3% and Operating Income of +1.0%; however, given the earnings decline in the first half, recovery of the profit margin in the second half will be key to achieving the plan.

Shareholder Returns

The dividend for Q2 was ¥0 per share, while the full-year dividend forecast is ¥80. Based on the full-year forecast EPS of ¥223.04, the Payout Ratio is approximately 35.9% (dividend only, based on Net Income), which is within a sustainable range if the earnings plan is achieved. However, first-half OCF was negative at -¥7.7B and Free Cash Flow was negative at -¥17.5B, meaning that the actual cash burden of dividends depends on an improvement in OCF during the second half.

Risk Factors

1. Risk of declining profitability: Within a low-margin structure characterized by an 11.1% gross margin and a 1.1% Operating Income margin, Revenue increased +3.0% while Operating Income declined -16.6%. This structure makes earnings highly sensitive to even minor fluctuations in procurement prices, personnel expenses, and logistics costs.

2. Cash flow and working capital risk: OCF was -¥7.7B, indicating that the company failed to generate cash despite recording Operating Income of ¥6.7B. Increases in trade receivables (-¥13.1B) and inventories (-¥9.8B) are putting pressure on working capital, making collection management a key issue.

3. Financial leverage and short-term funding risk: The company exhibits active use of debt, with an Equity Ratio of 25.3% and a debt-to-equity ratio of 2.96x. Short-term borrowings are increasing, creating a structure in which Free Cash Flow of -¥17.5B is being supplemented by Financing Cash Flow of +¥11.8B, indicating a high degree of dependence on the refinancing environment.

Industry Benchmark (Reference; Compiled by the Company)

Industry Benchmark (trading)

Profitability and Returns

The Net Income margin is significantly below the industry median, positioning the company among the less profitable companies in the industry.

Growth and Capital Efficiency

The Revenue growth rate is slightly below the industry median but falls within the IQR range.

※Source: Compiled by the Company

Key Takeaways from the Earnings Results

1. Despite revenue growth, the Operating Income margin has narrowed, making improvement in the gross margin and control of SG&A expenses, rather than revenue expansion, the factors determining earnings quality.

2. The progress rate of 33.7% against the full-year Operating Income forecast is below the standard 50%, indicating from the earnings data that substantial profit improvement is required in the second half under the plan.

3. While OCF is negative, capital expenditures have reached approximately three times depreciation and amortization expense. The efficiency of investment recovery and progress in improving cash flow are key points to monitor in future disclosures.

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not constitute a recommendation to invest in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly available earnings data. Investment decisions should be made at your own responsibility, and you should consult a professional adviser as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2026 Q2 performance was weak: modest sales growth did not translate into earnings growth, while operating cash flow remained materially negative. Revenue increased 3.0% YoY to ¥62.44bn. Operating income declined 16.6% YoY to ¥0.67bn. Ordinary income fell 18.0% YoY to ¥0.68bn. Net income declined 30.5% YoY to ¥0.45bn. Gross profit rose 1.8% YoY to ¥6.94bn, but this lagged revenue growth. Accordingly, gross margin contracted by approximately 15bp YoY to 11.1%. SG&A expenses rose 4.3% YoY to ¥6.27bn, exceeding revenue growth and creating negative operating leverage. The SG&A-to-sales ratio increased by roughly 12bp YoY to 10.0%. Operating margin compressed by approximately 26bp YoY to 1.1%, leaving very limited room to absorb cost inflation or pricing pressure. Net margin also fell by approximately 35bp YoY to 0.7%. Reported annualized ROE was 7.4%, below the 8% reference level, and was supported more by 3.96x financial leverage than by the low 0.7% net margin. Earnings quality was poor in the period, as operating cash flow was negative ¥0.77bn against net income of ¥0.45bn. The OCF/net income ratio was negative 1.71x and cash conversion, measured as OCF/EBITDA, was negative 0.75x. Inventory increased by ¥0.98bn and trade receivables increased by ¥1.31bn, consuming cash despite a ¥1.14bn increase in trade payables. Capital expenditure of ¥1.05bn was nearly three times depreciation and amortization of ¥0.35bn, indicating an investment phase but also deepening the negative free-cash-flow position. Free cash flow was negative ¥1.75bn. Financing cash flow of ¥1.18bn, including a ¥1.95bn increase in short-term loans, was needed to support investment, dividends and working-capital requirements. The full-year sales forecast appears broadly achievable at a 48.8% Q2 progress rate, but operating-income and net-income progress of 33.7% and 34.1%, respectively, imply a substantial second-half earnings recovery is required. The central financial issue for the remainder of FY2026 is whether margin recovery and working-capital normalization can fund continued investment without further increasing short-term borrowing.

Profitability Analysis

The reported annualized DuPont ROE of 7.4% is decomposed into a 0.7% net profit margin, 2.596x asset turnover and 3.96x financial leverage. The weakest component is clearly net margin, which fell from approximately 1.1% in the prior-year period to 0.7%. Asset turnover remains relatively high for a distribution-oriented healthcare business, reflecting the high-volume and low-margin business model. Financial leverage is the main offset to weak profitability, but it also elevates balance-sheet sensitivity when earnings decline. Gross margin fell to 11.1% from roughly 11.3% in the prior-year period, suggesting that procurement costs, product mix and/or pricing conditions prevented the company from fully converting sales growth into gross-profit growth. SG&A rose 4.3% YoY, versus 3.0% revenue growth, causing operating margin to decline to 1.1% from about 1.3%. This unfavorable operating leverage is a key concern because a 1.1% EBIT margin leaves earnings highly sensitive to small changes in gross margin or overhead. EBITDA was ¥1.02bn and EBITDA margin was 1.6%, also indicating limited operating-profit resilience. Interest coverage remained strong at 24.92x on an EBIT basis and 37.92x on an EBITDA basis, so current interest-servicing capacity is not the immediate constraint. The effective tax rate was 35.1%, producing a tax burden of 0.648, while the interest burden of 1.032 reflects the contribution of non-operating and extraordinary items relative to EBIT. Foreign-exchange gains were ¥0.22bn, while extraordinary income of ¥0.32bn exceeded extraordinary losses of ¥0.13bn; these items supported profit before tax but did not offset the underlying operating-income decline. The decline in profitability therefore appears primarily operational rather than financing-driven. A sustainable recovery requires gross-margin stabilization and SG&A discipline rather than reliance on non-operating or extraordinary gains.

Growth Assessment

Revenue growth of 3.0% YoY demonstrates continued top-line expansion, but the slower 1.8% growth in gross profit and decline in operating income indicate that revenue quality weakened. The business remains characterized by high asset turnover and low unit margins, making product mix, supplier terms and price pass-through important earnings drivers. Receivables rose 3.6% YoY to ¥23.97bn, broadly tracking sales growth, although the reported DSO of 70 days is elevated and requires close monitoring. Inventories increased 15.2% YoY to ¥7.40bn, materially faster than revenue, which may reflect inventory build for demand, supply assurance or mix changes but has increased working-capital intensity. Full-year revenue guidance is ¥127.98bn, implying 4.3% YoY growth; Q2 cumulative revenue represents 48.8% of that forecast and is close to the standard 50% progress rate. Full-year operating-income guidance is ¥2.00bn, up 1.0% YoY, but Q2 progress is only 33.7%, 16.3 percentage points below the standard 50% level. Full-year net-income guidance of ¥1.32bn requires a 34.1% Q2 progress rate, 15.9 percentage points below the standard pace. The company consequently needs a marked improvement in second-half operating income, supported by margin recovery, lower relative overhead growth, or seasonality. EBITDA of ¥1.02bn provides a more cash-neutral view of operating performance, but the 1.6% EBITDA margin remains thin. CapEx/depreciation of 2.98x indicates that management is investing above maintenance levels, which could support future capacity or productivity, although near-term returns need to justify the cash requirement. The outlook is therefore dependent less on achieving sales guidance and more on converting revenue into gross profit, operating income and cash flow.

Financial Health

Liquidity is adequate but not ample. The current ratio was 119.5%, above 1.0x and therefore not indicative of an immediate current-liability coverage shortfall, but below the 1.5x healthy reference level. The quick ratio was 96.6%, below 1.0x, indicating that inventories remain relevant to the coverage of current liabilities. Current assets of ¥38.61bn exceeded current liabilities of ¥32.30bn by ¥6.31bn. However, receivables represented 49.8% of total assets and inventories represented 15.4%, making liquidity dependent on collection performance and inventory turnover. The reported D/E ratio of 2.96x exceeds the 2.0x warning threshold and indicates an aggressive liability burden relative to equity under the reported definition. This is the root cause of the HIGH_LEVERAGE alert: total liabilities were ¥35.96bn, equal to 74.7% of total assets, against equity of ¥12.15bn. Context is partly mitigated by debt/capital of 23.2% and strong EBITDA interest coverage of 37.92x, but declining operating profit reduces the cushion over time. Interest-bearing debt was ¥3.67bn and debt/EBITDA was 3.58x, above the 2.5x investment-grade reference but below the 4.0x high-yield warning level. Short-term loans increased sharply to ¥2.35bn from ¥0.40bn a year earlier, a ¥1.95bn or 487.4% increase. This is the principal notable balance-sheet change and suggests increased reliance on short-dated funding for working capital and investment. The short-term debt ratio of 64.1% triggers the REFINANCING_RISK alert because a high share of debt requires repeated access to bank funding and exposes the company to refinancing conditions. Cash of ¥2.91bn covered short-term loans by 1.24x, providing some near-term protection, but cash declined 16.3% YoY. Long-term loans declined to ¥1.32bn from ¥1.52bn, so the change in funding mix was toward shorter maturities. This maturity profile is manageable while receivables are collected normally, but a slowdown in collections or inventory liquidation would increase liquidity pressure. Defined-benefit liability was ¥0.54bn and should remain part of ongoing liability monitoring.

Notable B/S Changes

Short-term loans: +¥1.95bn (+487.4%) to ¥2.35bn - substantial shift toward short-dated funding, consistent with financing support for working capital and investment; increases refinancing sensitivity. Inventories: +¥0.98bn (+15.2%) to ¥7.40bn - growth materially exceeded revenue growth and contributed to negative operating cash flow; monitor turnover and inventory quality. Property, plant and equipment: +¥0.58bn (+10.6%) to ¥6.09bn - reflects investment above depreciation, with capex of ¥1.05bn during the period; future utilization and return on investment are important. Accounts payable: +¥1.37bn (+7.4%) to ¥19.78bn - supplier financing partly offset receivable and inventory cash absorption, but continued reliance on payable expansion may be constrained. Cash and deposits: -¥0.56bn (-16.3%) to ¥2.91bn - reduced liquidity buffer alongside increased short-term borrowing and negative free cash flow.

Cash Flow Quality

Cash-flow quality was the weakest aspect of the Q2 result. Operating cash flow was negative ¥0.77bn despite net income of ¥0.45bn, resulting in an OCF/net income ratio of negative 1.71x, well below the 0.8x concern threshold. The root cause of the EARNINGS_QUALITY alert was working-capital absorption and cash tax payments rather than a lack of accounting profit alone. Trade receivables increased by ¥1.31bn and inventories increased by ¥0.98bn, together consuming ¥2.29bn of cash. Trade payables increased by ¥1.14bn, partly offsetting this outflow but not fully funding the receivable and inventory build. Reported DSO of 70 days exceeds the 60-day alert threshold, which is the basis for the HIGH_RECEIVABLE_DAYS flag. For a healthcare distributor, sizeable receivables and payment timing are structurally relevant, but the elevated DSO increases collection and liquidity sensitivity in a low-margin model. The impact is that reported earnings cannot presently be treated as fully self-funding. EBITDA was ¥1.02bn, while OCF/EBITDA was negative 0.75x, triggering the LOW_CASH_CONVERSION alert and showing that EBITDA did not convert into cash during the period. The accruals ratio was 2.5%, which remains below the 5% high-quality reference and provides some offsetting indication that broad accrual intensity is not excessive. Capital expenditures were ¥1.05bn, including ¥0.13bn of intangible-asset purchases, and exceeded depreciation and amortization by ¥0.70bn. Free cash flow was negative ¥1.75bn, so internally generated cash did not cover investment needs. Financing cash flow was positive ¥1.18bn, principally supported by increased short-term loans, demonstrating external funding dependence during the period. Operating cash flow was also negative in the prior-year period, indicating that the issue has persistence rather than being solely a one-quarter anomaly. The key indicators for improvement are receivable collection, inventory normalization, a return of OCF to positive territory, and reduced dependence on short-term loans to fund capital spending.

Dividend Sustainability

No Q2 dividend was paid. The full-year forecast dividend is ¥80 per share, versus forecast EPS of ¥223.04, implying a forecast dividend payout ratio of approximately 35.9%. This payout ratio is below the 60% sustainability reference and appears reasonable relative to forecast earnings. However, the current-period free cash flow was negative ¥1.75bn, so dividends were not covered by internally generated free cash flow in the first half. Cash dividends paid during the period were ¥0.49bn, while operating cash flow was negative ¥0.77bn, underscoring the importance of financing and balance-sheet liquidity. The sustainability of the planned dividend therefore depends on the anticipated second-half cash-flow recovery and on working-capital management. The company has retained earnings of ¥11.34bn, which provides an accounting buffer, but retained earnings do not eliminate the need for cash funding. With short-term borrowing increasing significantly, maintaining dividend payments alongside elevated capex should be evaluated against cash conversion rather than earnings alone. The forecast payout is not inherently aggressive, but dividend resilience would improve materially if operating cash flow turns positive and capital expenditure moderates relative to internally generated funds.

Risk Assessment

Business risks include Margin risk: gross margin of 11.1% and EBIT margin of 1.1% leave profit highly exposed to procurement cost inflation, reimbursement and pricing pressure, product-mix changes, and competitive discounting in healthcare distribution., Operating leverage risk: SG&A increased 4.3% YoY while revenue rose 3.0%, producing operating-margin compression; sustained overhead growth above sales growth would further weaken earnings., Working-capital risk: DSO of 70 days and a 15.2% YoY inventory increase increase exposure to delayed customer collections, inventory obsolescence and cash absorption., Execution risk on elevated investment: capex was 2.98x depreciation, so the return on current investment must improve sufficiently to support future profitability and cash generation..

Financial risks include High leverage alert: reported D/E of 2.96x exceeds the 2.0x threshold, increasing sensitivity of equity returns and liquidity to operational underperformance., Refinancing risk: 64.1% of debt is short term, and short-term loans rose ¥1.95bn YoY to ¥2.35bn; the funding structure relies more heavily on recurring refinancing., Cash-conversion risk: negative OCF of ¥0.77bn, negative OCF/net income of 1.71x, and negative free cash flow of ¥1.75bn indicate that current earnings are not funding operations and investment., Debt-capacity risk: debt/EBITDA of 3.58x is elevated versus the 2.5x reference, although interest coverage remains strong at 37.92x..

Key concerns include The LOW_OPERATING_EFFICIENCY alert is warranted because the 1.1% EBIT margin is below the 5% concern benchmark; modest adverse changes in gross margin can materially affect profit., The LOW_GROSS_MARGIN alert is warranted because 11.1% gross margin is below the 20% benchmark; this is structurally consistent with distribution businesses but still requires exceptional cost and working-capital discipline., The EARNINGS_QUALITY and LOW_CASH_CONVERSION alerts have direct investment-thesis implications: a recovery in reported profit without positive operating cash flow would not materially improve financial flexibility., The combination of margin compression, negative free cash flow and increased short-term borrowing is the highest-priority financial pattern to monitor in the second half..

Investment Implications

Key takeaways include Top-line momentum remains positive, with Q2 revenue up 3.0% YoY and broadly on track against full-year sales guidance., Earnings conversion deteriorated: operating income fell 16.6% YoY and net income fell 30.5% YoY despite revenue growth., The reported annualized 7.4% ROE is driven by high turnover and 3.96x leverage rather than a robust 0.7% net margin., Negative operating cash flow and negative free cash flow make working-capital normalization more important than reported earnings alone., The sharp shift toward short-term borrowing raises the importance of refinancing discipline and second-half cash generation., FY2026 profit guidance requires a meaningful second-half improvement because Q2 operating-income and net-income progress are materially below a standard 50% first-half pace..

Metrics to watch include Gross margin and operating margin, particularly whether the 11.1% gross margin and 1.1% EBIT margin recover in the second half., SG&A growth relative to revenue growth., DSO, trade receivables and inventory movement., Operating cash flow, OCF/net income and OCF/EBITDA conversion., Free cash flow after elevated capital expenditure., Short-term loan balance, debt/EBITDA and the share of short-term debt., Progress toward full-year operating-income guidance of ¥2.00bn and net-income guidance of ¥1.32bn., Dividend funding relative to operating cash flow and free cash flow..

Regarding relative positioning, The company exhibits the characteristics of a high-turnover healthcare distributor, but its profitability is currently below broad benchmark levels: EBIT margin is 1.1%, net margin is 0.7%, and reported annualized ROE is 7.4%. Interest coverage remains strong and debt/capital is moderate, but the reported D/E ratio, negative cash conversion and greater reliance on short-term borrowing create a more financially sensitive profile than would be implied by earnings alone.